Whalegun
Lobbying

Lykos Therapeutics's latest lobbying report covers Q2 2025, at $130K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Veterans.

Lykos Therapeutics

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Lykos Therapeutics lobbying by quarter
Lykos Therapeutics lobbying by quarter
QuarterAmountReports
Q4 2022$01
Q1 2023$150K2
Q2 2023$180K2
Q3 2023$150K2
Q4 2023$170K2
Q1 2024$180K2
Q2 2024$180K2
Q3 2024$220K2
Q4 2024$170K2
Q1 2025$150K2
Q2 2025$130K2
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$445K · 20 reports
  • Veterans$445K · 20 reports
  • Budget and appropriations$395K · 18 reports
  • Defense$395K · 18 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES20 reports
  • SENATE19 reports
  • White House Office2 reports
  • Veterans Affairs, Dept of (VA)1 reports

Firms it paid

Firm
In-houseLykos Therapeutics$1.1M11 quarters
Forbes-Tate$580K10 quarters

Former officials lobbying for it

Former position
CYNTHIA BROWNChief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002)Q1 2024
RYAN J TAYLORCD, S. Wicker (2013-2018); PA, Sen. Rep. Pol Comt (2012-2013); S. PA, Sen. Rep. Vice-Chair (2011-2012); PS, Rep. Lummis (2009-2010); Dep. CD, Sen. Barrasso (2007-2008); Dep. PS, S. Thomas (2007); Dep. CD, Sen. HELP (2005-2007); SA, S. Enzi (2004)Q1 2023

Lobbying reports

Filed by
25/07/21for Q2 2025In-house$90K
25/06/18for Q2 2025Forbes-Tate$40K
25/04/21for Q1 2025In-house$90K
25/04/14for Q1 2025Forbes-Tate$60K
25/03/14for Q3 2024Forbes-Tate$60K
25/01/21for Q4 2024In-house$110K
25/01/17for Q4 2024Forbes-Tate$60K
25/01/08for Q3 2024Forbes-Tate$60K
25/01/08for Q2 2024Forbes-Tate$60K
24/10/21for Q3 2024In-house$160K
24/10/17for Q3 2024Forbes-Tate$60K
24/07/22for Q2 2024In-house$120K
24/07/13for Q2 2024Forbes-Tate$60K
24/04/22for Q1 2024In-house$120K
24/04/14for Q1 2024Forbes-Tate$60K
24/01/22for Q4 2023In-house$110K
24/01/16for Q4 2023Forbes-Tate$60K
23/10/20for Q3 2023In-house$90K
23/10/17for Q3 2023Forbes-Tate$60K
23/07/20for Q2 2023In-house$120K